Status:
RECRUITING
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
Lead Sponsor:
Pfizer
Conditions:
Atopic Dermatitis
Eczema
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis. Atopic dermatitis, ...
Eligibility Criteria
Inclusion
- Patients older than 18 years of age at inclusion.
- Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator and eligible for abrocitinib according to its marketing approval.
- Patients that have been informed of the study procedures and have signed the consent.
Exclusion
- Patients for whom abrocitinib is contraindicated.
- Patients unable to follow and respect the study procedures and judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons.
- Patients not affiliated to the French social security system.
- Patients deprived of liberty, under guardianship, or unable to provide oral consent.
- Patients participating in a clinical study assessing a medicinal treatment (patients can participate in registries and observatories).
Key Trial Info
Start Date :
March 9 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
183 Patients enrolled
Trial Details
Trial ID
NCT05689151
Start Date
March 9 2023
End Date
December 31 2027
Last Update
December 8 2025
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens-Picardie - Site Nord
Amiens, Somme, France, 80080
2
CHU Besancon - Hopital Jean Minjoz
Besançon, France, 25000
3
Polyclinique Reims Bezannes
Bezannes, France, 51430
4
Chu Bordeaux Hopital Saint Andre
Bordeaux, France, 33075